Cediranib
AIDS-Related Plasmablastic Lymphoma
City of Hope Medical CenterSmall moleculePhase 1/2Active
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the AIDS-Related Plasmablastic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells AIDS Malignancy Consortium | Phase 1/2 | CCC |
Irinotecan National Cancer Institute (NCI) | Phase 1/2 | CCC |
Vorinostat National Cancer Institute (NCI) | Phase 1/2 | CCC |
FILGRASTIM City of Hope Medical Center | Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →